Twitter | Search | |
Search Refresh
HealthEconomics.Com 4h
A new white paper from COTA offers unique perspectives on , including input from Pfizer and Bristol-Myers Squibb executives. |
Reply Retweet Like
Vitaccess 9h
As France’s (HAS) publishes an ”Action plan for innovative drugs”, we look into the increased role for in French reimbursement process.
Reply Retweet Like
The Evidence Base® 6h
How could modern -mining techniques make the generation of more ? Discover more in our interview with Ulf Staginnus () now!
Reply Retweet Like
TARGET PharmaSolutions 5h
can provide major insights into how drugs are performing & its use in settings, which can improve . Learn more about our solution:
Reply Retweet Like
Emerald Clinics 15h
SOUND ON! Our Medical Director Dr. Alistair Vickery recently joined Wil Anderson on his Wilosophy podcast to talk about cannabinoid based medicines. Listen below!
Reply Retweet Like
Navneet Majhail, MD 8h
Reply Retweet Like
The Centre for Medicinal Cannabis 10h
Reminder: Call for abstracts to present at CMC's Conference within the themes of , , , , & . Deadline 29 February For more information please visit
Reply Retweet Like
The Evidence Base® Feb 18
How could we maximize the potential of in regulatory decision making? Discover insight from () in this original editorial now:
Reply Retweet Like
Video Journal of Biomedicine Feb 18
How does the use of first-line pembrolizumab monotherapy for in real-world oncology practice compare in clinical trials? Find out more in the latest video published in
Reply Retweet Like
Harriette Van Spall, MD MPH Feb 13
🔥 summary of vs . These shouldn’t be considered binary; randomization can include through that mirrors realworld care. Pragmatic eligibility, organization, followup can ⬇️research burden on clinicians & pts. Link below
Reply Retweet Like
The Evidence Base® Feb 17
Do you need to learn more about how agencies will work with for ? Join us at as we explore your essential questions. Register now at:
Reply Retweet Like
Diabetes Technology 19h
Does real-world evidence have a place in regulatory decision making? An interview with David Klonoff
Reply Retweet Like
Lynn Lund Feb 11
More steak, less sizzle. Read Jeff Trotter’s second prediction for in 2020.
Reply Retweet Like
The Evidence Base® Feb 17
Check out our latest feature on the current and future states of utilizing and in decision making – discover exclusive expert insight from , and more! View now:
Reply Retweet Like
Syneos Health 18h
Welcome to ! We look forward to syncing up with you throughout the show at booth 201 and tomorrow afternoon when our experts discuss the importance of and new FSP models.
Reply Retweet Like
ISPE_Exchange Feb 14
Friday is a great day to register for ☀️! will be one of the speakers for the session "Translational collaborations between and to enhance " Full agenda and registration here:
Reply Retweet Like
Lynn Lund Feb 11
Can have more applications than just demonstrating value? Read Jeff Trotter’s prediction for 2020.
Reply Retweet Like
The Centre for Medicinal Cannabis Feb 17
***Call for abstracts*** CMC Conference, London, 16-17 April 2020 Themes , , , , and . Deadline 29 February 2020 Details 👇
Reply Retweet Like
Health Analytics Collective Feb 15
From shortening the timeline to mapping specific patient populations, is transforming the industry. Learn more from Erin Booth, Manager of Regulatory & Medical Writing at :
Reply Retweet Like
Clinerion Feb 14
🌎Will you be at any of these international events? Do you have needs? > Our technology is a match maker between sponsors and and . It also enables the generation of . Let's discuss! 🤝
Reply Retweet Like